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Activation of NRG1-ERBB4 signaling potentiates
mesenchymal stem cell-mediated myocardial repairs
following myocardial infarction
X Liang1, Y Ding1,2, Y Zhang1, Y-H Chai1,2, J He1, S-M Chiu1, F Gao1, H-F Tse*,1,3,4,5 and Q Lian*,1,3,4,5,6
Mesenchymal stem cell (MSC) transplantation has achieved only modest success in the treatment of ischemic heart disease owing
to poor cell viability in the diseased microenvironment. Activation of the NRG1 (neuregulin1)-ERBB4 (v-erb-b2 avian erythroblastic
leukemia viral oncogene homolog 4) signaling pathway has been shown to stimulate mature cardiomyocyte cell cycle re-entry and
cell division. In this connection, we aimed to determine whether overexpression of ERBB4 in MSCs can enhance their cardio-
protective effects following myocardial infarction. NRG1, MSCs or MSC-ERBB4 (MSC with ERBB4 overexpression), were
transplanted into mice following myocardial infarction. Superior to that of MSCs and solely NRG1, MSC-ERBB4 transplantation
significantly preserved heart functions accompanied with reduced infarct size, enhanced cardiomyocyte division and less
apoptosis during early phase of infarction. The transduction of ERBB4 into MSCs indeed increased cell mobility and apoptotic
resistance under hypoxic and glucose-deprived conditions via a PI3K/Akt signaling pathway in the presence of NRG1.
Unexpectedly, introduction of ERBB4 into MSC in turn potentiates NRG1 synthesis and secretion, thus forming a novel NRG1-
ERBB4-NRG1 autocrine loop. Conditioned medium of MSC-ERBB4 containing elevated NRG1, promoted cardiomyocyte growth
and division, whereas neutralization of NRG1 blunted this proliferation. These findings collectively suggest that ERBB4
overexpression potentiates MSC survival in the infarcted heart, enhances NRG1 generation to restore declining NRG1 in the
infarcted region and stimulates cardiomyocyte division. ERBB4 has an important role in MSC-mediated myocardial repairs.
Cell Death and Disease (2015) 6, e1765; doi:10.1038/cddis.2015.91; published online 21 May 2015
Although mesenchymal stem cell (MSC)-based cell trans-
plantation is a promising and novel approach for cardiac repair
following myocardial infarction (MI) that involves paracrine
factors and cardiovascular differentiation,1–4 the poor survival
and engraftment of transplanted stem cells within the ischemic
myocardium remain major limitations to this process. Numer-
ous strategies have been used to improve MSC-based
therapeutic potential, among which genetic modification has
drawn considerable attention. Introducing genes into MSCs to
enhance cell viability, mobility and angiogenesis has been
explored.5–8 For example, overexpression of the anti-apoptotic
factor Bcl-2 (B-cell lymphoma 2) in MSCs enhances survival
capacity and improves cardiac performance during MI follow-
ing transplantation.9 Similarly, MSCs with IGF1 (insulin-like
growth factor 1) overexpression induce stem cell mobilization
and increase angiomyogenesis that subsequently contribute
to myocardial repair.10 Nevertheless the effects of these
genetically engineered MSCs on adult mature cardiomyocyte
regeneration are unclear. Identification of novel genes or
pathways that both ameliorate MSC properties and initiate
endogenous cardiomyocyte regeneration in situ will thus
provide crucial benefits.
Following examination of adult hearts, Bersell et al.11
recently revealed that NRG1 (neuregulin1) can stimulate
mononuclear mature cardiomyocytes to re-enter the cell
cycle and DNA duplicate status through the NRG1-ERBB
signaling pathway. Strategic targeting of the signaling
complex of NRG1 and its tyrosine kinase receptors, ERBB2
(v-erb-b2 avian erythroblastic leukemia viral oncogene
homolog 2) and ERBB4 (v-erb-b2 avian erythroblastic
leukemia viral oncogene homolog 4) has demonstrated
positive outcomes following heart failure in animal
models.12–14 NRG1, a member of the epidermal growth
factor family, has been comprehensively documented as an
essential paracrine regulator of cell–cell communication
through activation of its ERBB tyrosine kinase receptors,
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and is indispensable in heart development and adult cardiac
physiology.11,15–19 The recombinant human NRG1 has been
used in clinical trials to treat chronic heart failure in China
and Australia (ClinicalTrials.gov identifiers NCT01131637,
NCT01258387), in which it proved to enhance heart function
and reverse remodeling.20,21 ERBB2 acts as a non-ligand
binding, pre-activated co-receptor that needs to heterodi-
merize with ERBB4 and forms an ERBB2/ERBB4 complex
upon activation by NRG1. In contrast, ERBB4 possesses the
capability of homodimerization and activates PI3K/Akt (v-akt
murine thymoma viral oncogene homolog 1) signaling that
facilitates cell survival. Although this crucial discovery
suggests the potential of using NRG1 as a therapeutic agent
for cardiac repair, numerous challenges must be addressed
before it can become a reality. First, the circulating half-life of
NRG1 is extremely short (~30 min),14 thus the interval during
which it can be delivered is limited. Attempts have beenmade
to prolong the NRG1 half-life by using a controlled delivery22
or by combining it with adipose-derived stem cell
transplantation.23 Second, a relatively small population
(10%) of cardiomyocytes in the adult heart are mononu-
cleated and although systematic administration of NRG1
initiates cytokinesis in vivo, it only corresponds to ~ 0.3% of
the mononuclear cardiomyocytes present following MI.11
Third, the receptor presenting on the targeting cells has a
vital role in managing whether the cells respond to NRG1
stimuli or not. These sub-optimal results may attribute to the
low penetration of NRG1 or in the ischemic myocardium that
consequently limits its therapeutic efficiency.
Both MSC therapy and targeting the NRG1-ERBB complex
hold great potential for treating cardiac diseases. Our
hypothesis is therefore to combine these advantages by
engineering MSCs and studying whether and how these cells
can confer cardiac protection following transplantation into
infarcted hearts. To this end, we first screened expression of
ERBB receptors in mouse MSCs and determined that NRG1
and ERBB2, but not ERBB4, were expressed in MSCs. As
ERBB2 is incompetent to bind NRG1, transplanting unmodi-
fied MSCs that lack ERBB4 cannot activate NRG1-ERBB
signaling, and thus stultifies the existing NRG1 in the infarcted
myocardium.24 We introduced ERBB4 expression into MSCs
(MSC-ERBB4) and transplanted them into MI model. MSC-
ERBB4 not only significantly preserved heart functions
accompanied with reduced infarct size and enhanced cardi-
omyocyte division, but also improved MSC survival and
created an autocrine loop in the NRG1-ERBB4-NRG1
signaling pathway. These results suggest that engineering
ERBB4 in MSCs could be an novel strategy to benefit both
MSCs and cardiomyocytes for enhancing efficacy of MSC-
based transplantation in heart infarction.
Results
Expression of ERBB4 in MSCs didn’t alter MSCs
differentiation potential. MSCs isolated from tibias and
Figure 1 Exogenous ERBB4 was successfully transduced in MSCs. (a) RT-RCR screening of NRG1-ERBB expression in MSCs. MSC expressed NRG1 and ERBB2, but not
ERBB4. (b) MSCs were successfully transduced with pGFP or pER4-GFP (map shown in Supplementary Figure 2), confirmed by using a GFP-positive signal detected under a
fluorescent microscope (b1). RT-PCR (b2) and western blotting (b3) confirmed successful manipulation of ERBB4 into MSCs. Elevated p-ERBB4 occurred when additional NRG1
was added. p-ERBB4, phosphorylated ERBB4. (c) Lentiviral-transduced MSCe and MSC-ERBB4 possessed multi-lineage differentiation capacity, confirmed by staining (c1) and
lineage specific gene expression (c2). (d) Neither MSCe nor MSC-ERBB4 injection raised malignant formation during 8 weeks of observation, with mouse embryonic stem cells
as positive control. mESCs, mouse embryonic stem cells. n= 4 for each group
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Figure 2 Transplantation of MSC-ERBB4 reduced fibrosis and improved heart function. Heart function was measured using a pressure-volume conductance catheter system
4 weeks after injection of NRG1, MSCe or MSC-ERBB4. (a) Representative single PV-loop recording images are shown. MI resulted in a rightward shift in the loop, which
increased the volume and depression of the ESPVR slope (aii versus ai, red line). MSC-ERBB4 but not MSCe (av versus aiv) or NRG1(av versus aiii) reduced the volume and
restored the original slope of the ESPVR. (b) Enhanced peak velocities of pressure change (dp/dt) occurred during isovolumic contraction (+dp/dt) and isovolumic relaxation
(− dp/dt) in mice injected with MSC-ERBB4. (c) ERBB4 overexpression reduced scar formation following MI. Masson’s trichrome staining indicated the thinning and expansion of
the infarct scar (blue color) in the MI group (cii versus ci) and was attenuated in the MSC and NRG1 treated groups at 4 weeks post-MI (ciii, civ and cv). Representative
photomicrographs for each group are shown. (d) Quantification of fibrotic area presented as the percentage of LVarea positively stained with Masson trichrome. (e) Quantification
of LV wall thickness. MSC-ERBB4 transplantation resulted in smaller infarct zone within the total LV area compared with that in the MI, MI+NRG1 and MI+MSCe groups and
increased infarct wall thickness. LV, left ventricular; ESPVR, end-systolic pressure-volume relationship. n= 12 for each group
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spindle-like MSCs (Supplementary Figure 1) were ex vivo
culturing until passage 4 to exclude non-adherent hematopoietic
cells. The expression profile of ERBB family and its ligand
NRG1 were examined by RT-PCR (reverse transcription
polymerase chain reaction) following MSCs characterization
(Supplementary Figure 1). MSCs were positive for NRG1 and
ERBB2, but negative for ERBB3 and ERBB4 (Figure 1a).
MSCs were transduced with a lentiviral vector containing
the ERBB4 cDNA and GFP (green fluorescent protein;
MSC-ERBB4) or GFP (MSCe; plasmid map showed in
Supplementary Figure 2). Fluorescence signal was observed
in both MSCe and MSC-ERBB4 (Figure 1b1). ERBB4 was
detected in MSC-ERBB4, but not MSCe (Figure 1b2 and b3).
The expression of phosphorylated ERBB4 (p-ERBB4),
was increased in MSC-ERBB4 under NRG1 treatment
(Figure 1b3). The multiple differentiation potential of adipo-
gensis, chondrogenesis and osteogenesis was not affected
after lentiviral manipulation (Figure 1c1 and c2). To determine
the safety of introducing ERBB4 into MSCs, we tested the
risk of malignant transformation. MSCe and MSC-ERBB4
were subcutaneously injected into NOD-SCID mice, with
mouse embryonic stem cells (mESCs) serving as a positive
control. After an 8-week observation period, neither MSCe
nor MSC-ERBB4 induced tumorgenesis, whereas macro-
scopic tumor formation was observed at the mESCs injection
site (Figure 1d).
MSC-ERBB4 transplantation reduces infarction size and
preserves heart function. To evaluate whether overexpres-
sing ERBB4 generates an enhanced therapeutic effect of
MSCs, we transplanted MSC-ERBB4, MSCe and saline
controls into a mouse model of heart infarction. To demon-
strate the advantages of MSC-ERBB4 therapy compared with
the direct application of NRG1, another group of mice were
treated with NRG1 injection following MI. A PV-loop
(pressure-volume loop) provides continual assessment of
LV (left ventricular) pressure and relative volume to indicate
cardiac performance. An ESPVR (end-systolic pressure-
volume relationship) refers to the maximal pressure that
can be produced by the ventricle at any given LV volume, and
provides an index of myocardial contractility. LAD (left
anterior descending artery) ligation caused a shift to the
right in the loop to increase the volume and depression
slopes of the ESPVR (Figure 2aii versus ai, red line),
indicating dilated cardiomyopathy, in accordance with the
morphological changes shown in Figure 2cii. MSC-ERBB4
treatment reduced the volume and restored the slope of the
ESPVR more than NRG1 or MSCe injection, indicating that a
more powerful contractility occurred (Figure 2av versus aiii
and aiv). The peak velocity of pressure change (dp/dt) is a
reliable index used to measure ventricular function, because
parameters such as afterload, wall motion abnormalities and
variations in ventricular anatomy and morphology that appear
in a diseased model do not affect the results. LV hemody-
namic and volume data at week 4 is shown in Table 1. The
data implied that the index for contractility that occurred
during isovolumic contraction, +dp/dt, in the NRG1 and cell
transplantation groups was much higher than that of the MI
group (Table 1 and Figure 2b), whereas MSC-ERBB4
demonstrated superior performance to NRG1 or MSCe
(Table 1 and Figure 2b, Po0.05 versus MI+NRG1, Po0.05
versus MI+MSCe). A similar pattern was observed in –dp/dt,
an index for LV diastolic function (Table 1 and Figure 2b,
Po0.05 versus MI+NRG1, Po0.05 versus MI+MSCe).
These results showed that MSCs with ERBB4 expression
reduced post-MI deterioration in cardiac function, with a
cardio-protective effect significantly greater than that of solely
NRG1 or MSCs without ERBB4.
Table 1 Summary of cardiac functional parameter
HR (per min) ESP (mmHg) EDP (mmHg) +dp/dt (mmHg/s) −dp/dt (mmHg/s)
Sham 201.20±46.67 75.17±7.20 5.14±5.22 2891.31±215.27 −2327.65±259.57
MI 228.90±43.74 52.47±13.42a 5.60±9.56 1126.19±229.84a − 669.05±213.08a
MI+NRG1 201.43±38.92 62.58±18.46b 6.45±8.13 1607.62±239.19a,b −1201.64±345.76a,b
MI+MSCe 193.77±28.72 74.32±15.87b 6.62±6.70 1637.91±±159.98a,b −1318.61±530.07a,b
MI+MSC-ERBB4 193.81±45.05 75.25±10.35b 6.58±6.03 2199.95±143.42a,b,c,d −1769.15±275.20a,b,c,d
Abbreviations: HR, heart rate; ESP, end-systolic pressure; EDP, end-diastolic pressure
aPo0.05 versus sham group
bPo0.05 versus MI group
cPo0.05 versus MI+NRG1 group
dPo0.05 versus MI+MSCe group
Figure 3 ERBB4 overexpression enhanced MSC survival through enhancing the mobility and anti-apoptosis by activating the PI3K/Akt pathway. (a) Surviving MSCe and
MSC-ERBB4 were detected using anti-GFP antibody at 4 weeks post-MI. Representative images are shown. Quantification revealed that ERBB4 overexpression significantly
improved MSC survival. Scale bar= 200 μm. n= 12 for each group. (b) The NRG1-ERBB4 pathway enhanced MSC mobility. (b1) Experiment setting: MSCe or MSC-ERBB4
were seeded in the upper chamber of a transwell unit, with NRG1 added to the lower chamber to serve as an attractor. (b2) After hypoxic exposure for 6 hours, MSCe and MSC-
ERBB4 exhibited equivalent movements (b2i, NS); however, MSC-ERBB4 demonstrated more aggressive mobility in the presence of NRG1 than MSCe did (b2ii, Po0.05 versus
MSCe). Scale bar= 200 μm. (c) Annexin V/PI staining followed by flow cytometry were conducted to study the dynamic apoptotic rates of MSCe and MSC-ERBB4. Under
hypoxia challenge, MSCe stayed incooperative to NRG1 (cii–cv), but the apoptotic rate of MSC-ERBB4 was attenuated by NRG1 in a dose-dependent manner under hypoxic
condition (cvii–cx). The experiment was repeated three times and statistical analysis was performed (cxi). (d)Overexpressing ERBB4 in MSC reduced hypoxia-related apoptosis
through the PI3K/Akt pathway. Additional NRG1 increased p-Akt accumulation in MSC-ERBB4 (dviii versus vii), but not in MSCe (dii versus di), and this effect could be partially
blocked either by PI3K/Akt inhibitor LY294002 (dxii versus dviii), or anti-ER4 antibody (dxi versus dviii). The same trend was exhibited in Bcl-2 expression. The aforementioned
western blotting was repeated three times and representative images are shown. Bcl-2, B-cell lymphoma 2; p-Akt, phosphorylated Akt; t-Akt, total Akt; anti-ERBB4, anti-ERBB4
antibody
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Gross histological examination was performed using
Masson trichrome staining, in which a fibrotic area was
indicated by a blue color. The infarct size was quantified by
the average ratio of fibrosis area to the total LV area (percent
fibrosis area). The percentage fibrotic area in the MI group
was transmural, occupying 55.4±4.5%of the LV (Figure 2cii and
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d), whereas the fibrosis was remarkably attenuated by NRG1
and stem cell treatment (Figure 2ciii, civ, cv and 2d). NRG1
injection achieved comparable beneficial effects as MSCe, but
MSC-ERBB4 substantially outperformed NRG1 and MSCe,
exhibiting a much smaller fibrotic area (Figure 2d, Po0.05
versus MI+NRG1, Po0.05 versus MI+MSCe), and more
effectively preserved LV wall thickness (Figure 2e, Po0.05
versus MI+NRG1, Po0.05 versus MI+MSCe).
Overexpressing ERBB4 potentiates MSC survival by
effective homing and activation of the PI3K/Akt pathway.
Given that effective cell retention is essential for the beneficial
effect of MSCs, we examined whether ERBB4 overexpres-
sion could enhance MSC survival following MI. As both
MSCe and MSC-ERBB4 were successfully labeled with a
GFP reporter, cell tracking was achieved using anti-GFP
antibodies post-engraftment. Four weeks after cell injection,
immunostaining with anti-GFP revealed that MSCs were still
detectable (Figure 3a). As expected, significantly more GFP-
positive cells were identified in the MSC-ERBB4 group than in
the MSCe (Figure 3a, Po0.05 versus MSCe), demonstrating
an ~2.5-fold improvement in cell survival.
Hypoxia in the ischemic area of the post-MI heart is thought
to be the main cause of death of the transplanted MSCs.25 We
used a reduced-serum medium containing 0.5% fetal bovine
serum (FBS) and hypoxic culture (1% O2, 4% CO2) to treat
MSCs with the intention of reproducing oxygen-glucose-
deprived conditions in vivo. Abundant evidence supports fast
mobilization and retention of MSCs at sites of injury following
systemic or local intra-tissue infusion in the MI model.26–28 We
thus determined whether ERBB4 overexpression would equip
MSCswith superior mobility. After 6 hours hypoxic exposure in
a transwell culture system, MSCe and MSC-ERBB4 demon-
strated almost equivalent movement (Figure 3b2i, NS).
Nonetheless in the presence of NRG1, notably enhanced
migration was observed in MSC-ERBB4 towards its ligand
NRG1, whereas MSCe did not readily react to the NRG1
treatment (Figure 3b2ii, Po0.05), indicating that the NRG1-
ERBB4 pathway favorably affected cell mobility. It is relevant to
guarantee a better MSC homing in vivo, as NRG1 expression
is still detectable in MI hearts.19
The anti-apoptosis potential of MSC-ERBB4 was investi-
gated using Annexin V/PI (propidium iodide) based flow
cytometry analysis. No significant apoptosis was detected in
cells cultured in normal conditions (normoxia, 15% FBS;
Figure 3ci and cvi). Nevertheless, both MSCe and MSC-
ERBB4 demonstrated a sensitive response to oxygen-
nutrition deprivation (hypoxia, 0.5% FBS) by exhibiting an
Figure 4 ERBB4 overexpression in MSCs provoked cardiomyocyte division and reduced cardiomyocyte loss. (a) Mature cardiomyocyte marker α-actinin and proliferation
marker Ki67 indicated that cardiomyocytes underwent mitosis. Both MSCe and MSC-ERBB4 transplantation-stimulated cardiomyocyte proliferation in remote and adjacent areas.
Representative images for each group are shown. Quantification indicated that MSC-ERBB4 induced more cardiomyocyte division than MSCe. Scale bar= 200 μm. n= 8 for
each group. (b) TUNEL-labeled apoptotic cardiomyocytes at 48 h after MI. Representative images are shown. MSC-ERBB4 transplantation provided better protection of
cardiomyocytes against apoptosis than MSCe did. n= 8 for each group
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increased Annexin V positive population up to ~ 20% (Figure
3cii and cvii). To examine the role of NRG1-ERBB4 in cell
apoptosis, a gradient concentration of NRG1 was added. In
contrast to MSCe that stayed unresponsive to NRG1 (Figure
3ciii to cv), the apoptotic rate of MSC-ERBB4 was attenuated
in response to NRG1 treatment administered in a dose-
dependent manner, with the most significant inhibition
apparent when 50 ng/ml NRG1 was applied (Figure 3cviii to
cx and cxi). These results demonstrated that ERBB4 expres-
sion was essential in the response of MSC to the NRG1-
mediated anti-apoptotic effect.
The mechanism involved in ERBB4-mediated cell protection
against hypoxia is likely regulated by activation of the PI3K/Akt
pathway.29 The activation of Akt refers to survival signals
produced by the altered expression of anti-apoptotic protein,
such as Bcl-2, or phosphorylating pro-apoptotic protein, such as
Bad (Bcl-2-associated death promoter).We investigatedwhether
the mechanism of cytoprotection driven by NRG1-ERBB4
signaling correlated with the PI3K/Akt pathway. The expression
of total Akt (t-Akt), phosphorylated Akt (p-Akt), and Bcl-2 were
examined by western blotting. In MSCe, the intensity of p-Akt
was weaker in the cells treated with the Akt inhibitor LY294002
than in those that were untreated (Figure 3div versus di),
suggesting that the Akt inhibitor effectively inhibited activation of
Akt. We determined that Akt activity was not reliant on NRG1,
because solely NRG1 treatment in MSCe did not increase p-Akt
compared with those left untreated (Figure 3dii versus di). In
addition, the combination of NRG1 and LY294002 did not alter
the expression level of p-Akt (Figure 3div versus dvi). Regarding
MSC-ERBB4, we observed that NRG1 treatment induced
accumulation of p-Akt (Figure 3dviii versus dvii), and this
phosphorylation of Akt by NRG1 was nullified by an additional
Akt inhibitor LY294002 (Figure 3dxii versus dviii). In addition, the
amount of upregulated p-Akt was remarkably decreased when
ERBB4 expression was neutralized by anti-ERBB4 antibody
treatment (Figure 3dxi versus dviii), indicating that NRG1-
induced PI3K/Akt activation occurred through ERBB4 expres-
sion in MSCs. The same expression pattern to p-Akt was
observed with Bcl-2. The data obtained in the MSC-ERBB4
suggested that the NRG1-ERBB4 pathway functioned through
phosphorylated activation of Akt that further upregulated Bcl-2
expression and thereby protected cells from apoptosis.
Activation of NRG1-ERBB4 signaling potentiates MSC-
mediated myocardial repairs. An intriguing role of the NRG1-
ERBB4 pathway with respect to cardiac regenera-
tive medicine is that NRG1 induces mature cardiomyocytes
to re-proliferate.11 We consequently performed double immu-
nostaining against α-actinin, a marker of mature cardiomyo-
cytes, and Ki67, a marker located in the nucleus that indicates
a
c
b
Figure 5 Conditioned medium of MSC-ERBB4 protects cardiomyocytes. (a) The conditioned medium of MSC-ERBB4 promoted cardiomyocyte growth, which was blunted by
anti-NRG1 antibody. (b) More Ki67pos cells were found in α-actininpos cardiomyocytes cultured with conditioned medium of MSC-ERBB4 than that of MSCe, indicating a more
prosper cell dividing. The number of Ki67pos cells declined when anti-NRG1 antibody was applied into conditioned medium of MSC-ERBB4. Scale bar= 200 μm. (c) The
conditioned medium of MSC-ERBB4 prevented cardiomyocytes from senescence, which was erased by anti-NRG1 antibody. (d) The conditioned medium of MSC-ERBB4
prevented cardiomyocytes from apoptosis by enhancing p-Akt and Bcl-2 expression. DAPI, 4',6-diamidino-2-phenylindole; CM, conditioned medium; Bcl-2, B-cell lymphoma 2;
p-Akt, phosphorylated Akt; t-Akt, total Akt; anti-NRG1, anti-NRG1 antibody
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proliferative status. In accordance with previous findings, very
few cardiomyocytes underwent proliferation under physiological
conditions (Sham group, data not shown).30 No Ki67-positive
cardiomyocytes were identified at various time points (24 h,
48 h, 7 days, 14 days, 28 days) in adult mice following infarction
(MI group, data not shown). Nonetheless after stem cell
transplantation, very small numbers of α-actinin and Ki67
double-positive cells were identified in both the MSCe group
and MSC-ERBB4 group after infarction (Figure 4a). More Ki67-
positive cells in the MSC-ERBB4 group than MSCe group were
also observed, in both MI adjacent and remote region
(Figure 4a, Po0.05).
The balance between cell proliferation and apoptosis is
regarded as determinant in tissue regeneration. We next
compared the apoptotic cell death among groups at 48 h after
MI. As shown in Figure 4b, TUNEL (terminal deoxynucleotidyl
transferase dUTP nick-end labeling) positive cardiomyocytes
was reduced in MSCe treated group, but a more significant
decrease was observed in the MSC-ERBB4 treated group
(Figure 4b, Po0.05).
Cardiomyocytes can be induced to proliferate by activating
NRG-ERBB4 signaling and, thus, produce global improve-
ments in cardiac function.11,14 We have demonstrated that
MSC-ERBB4 injection induces cardiomyocyte proliferation
and anti-apoptosis (Figure 4a and b). To seek in vitro
evidence to support this finding, we investigated the
possibility of MSC-ERBB4-mediated cardioprotection
through three processes: cell proliferation, senescence and
apoptosis. As the surface area of a 96-well transwell chamber
(0.143 cm2 per well) might not have been sufficient or
supportive for cardiomyocyte growth and immuno-
staining might be too obscure to present on the transwell
membrane, we used concentrated conditioned medium
collected from MSCe and MSC-ERBB4 following exposure
to hypoxia for 24 h and evaluated their effects on cardiomyo-
cytes, respectively. The primary neonatal cardiomyocytes,
characterized by expression of the cardiac marker α-actinin
(Supplementary Figure 3), were treated with conditioned
medium and then subjected to hypoxic stress. Twenty-
four hours later, MTT (3-(4,5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide) assay was conducted and
revealed distinct cell growth of cardiomyocytes supplemen-
ted with the conditioned medium of MSC-ERBB4, compared
with that of MSCe (Figure 5a, Po0.05 versus MSCe). In
accordance with the MTT results, more Ki67-positive cells, a
marker indicating active phases of the cell cycle, were found
in α-actinin positive cardiomyocytes cultured in the condi-
tioned medium of MSC-ERBB4, compared with that of MSCe
(Figure 5b, Po0.05 versusMSCe). The conditioned medium
of MSC-ERBB4 also more efficiently protected cardiomyo-
cytes against senescence than the conditioned medium of
MSCe (Figure 5c, Po0.05 versus MSCe). The conditioned
medium of MSC-ERBB4 protected cardiomyocytes against
apoptosis by activating p-Akt and increasing anti-apoptotic
protein Bcl-2 (Figure 5d). These data collectively suggested
that the genetic manipulation of ERBB4 induced beneficial
secretome in conditioned medium, through which cardio-
myocytes were protected from hypoxic stress.
Overexpressing ERBB4 in MSCs unexpectedly upregu-
lated its ligand NRG1 to form an NRG1-ERBB4 autocrine
loop. We examined NRG1 synthesis and secretion level in
MSCe and MSC-ERBB4 by performing western blotting and
enzyme-linked immunosorbent assay (ELISA) assays. Unex-
pectedly, we observed that the NRG1 level was significantly
elevated in MSC-ERBB4, but not in MSCe, both in cellular
(Figure 6a, Po0.05 versus MSCe) and concentrated condi-
tioned medium (Figure 6b, Po0.05 versus MSCe). Hypoxia
treatment further enhanced the NRG1 protein level in MSC-
ERBB4 (Figure 6b, Po0.05 versus MSCe). ERBB4 manip-
ulation upregulated NRG1, but did not alter the expression
pattern of other ERBB family members (Figure 6c). Increased
NRG1 expression caused by ERBB4 expressed in MSCs
indicated that an NRG1-ERBB4-NRG1 autocrine loop
existed. To test this hypothesis, we performed multiple
transient transfection experiments using pER4-GFP plasmid,
Figure 5 (Continued)
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by which ERBB4 expression in MSCs can be reported and
quantified using the population of GFP-positive MSCs in flow
cytometry analysis. The NRG1 protein level among ERBB4
transfected cells was examined using western blotting. We
determined that a gradual increase in the NRG1 level
(Figure 6d1) was associated with an increasing number of
GFP-positive cells (Figure 6d2). The increased expression of
ERBB4 contributed to upregulation of NRG1, thus forming an
NRG1-ERBB4-NRG1 autocrine loop. To confirm the intrinsic
coupling of ERBB4 and NRG1, we performed another
transfection experiment using human stromal 293FT cells.
We detected an upregulated NRG1 protein level after the
overexpression of ERBB4 (Figure 6e), suggesting that the
NRG1-ERBB4-NRG1 loop indeed is conservative in mouse
and human species.
Transplantation of MSC-ERBB4 restores declined NRG1
in infarction region. Considering the cardiomyocyte pro-
liferation induced by MSC-ERBB4 injection together with the
documented roles of NRG1-ERBB4 signaling in stimulating
cardiomyocyte re-proliferation, we examined whether
transplantation of MSC-ERBB4 could restore declined
NRG1 in infarction region. As expected, significantly
decreased level of NRG1 was detected in the infarcted site
compared with that of the remote non-infarcted site
(Figure 7). However, the transplantation of MSC-ERBB4
could restore declining NRG1 level post-MI, but neither
MSCe nor NRG1 (Figure 7).
As the activation of NRG1-ERBB4 autocrine loop leaded to
increasing NRG1 level (Figure 6), we intended to examine
the role of self-activated NRG1 on the cardiomyocytes.
Figure 6 Overexpression of ERBB4 in MSCs unexpectedly activates a novel NRG1-ERBB4-NRG1 autocrine loop. Overexpressing ERBB4 in MSCs unexpectedly
upregulated the synthesize and secretion of its ligand NRG1, detected by conducting western blotting (a) and ELISA (b), respectively. (c) Overexpressing ERBB4 in MSCs
upregulated NRG1, but did not alter expression of ERBB2. ERBB3 remained negative before and after ERBB4 overexpressing. (d) Multiple transient transfections using pER4-
GFP confirmed that upregulated NRG1 was attributed to exogenous ERBB4 overexpression. (d1) With increased transfection frequency shown by encircular numbers
(d1①②③④⑤), GFP signal, which indicated transfection efficiency, was escalating accordingly, from 1.2% for the first time (d1①) to 32.7% for the fifth time (d1⑤). (d2) The
expression of NRG1 was upregulated along with increased transfection efficiency. (e) In human 293FT cells, NRG1 expression was upregulated after ERBB4 transduction. The
aforementioned experiments were repeated three times and representative images are shown. 293FTe, 293FTexpressing pGFP; 293FT-ERBB4, 293FTexpressing pER4-GFP
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We introduced anti-NRG1 antibody to neutralize the
soluble NRG1 in the concentrated conditioned medium of
MSC-ERBB4. The application dosage (10 μg/mL) was pro-
vided far beyond sufficient, according to ELISA results
(3000 pg/mL in conditioned medium of MSC-ERBB4,
Figure 6b), to allow an effective inhibition. When anti-NRG1
was applied, the number of proliferating cardiomyocytes
declined to a level comparablewith that in conditionedmedium
of MSCe (Figure 5a and b), suggesting that the NRG1 in the
MSC-ERBB4 conditioned medium indeed was responsible for
stimulating cardiomyocytes proliferation. The conditioned
medium of MSC-ERBB4 protected cardiomyocytes from
senescence, but anti-NRG1 antibody erased this effect
(Figure 5c). These data collectively indicated that the
transplantation of MSC-ERBB4 might serve as an NRG1
factory to restore declined NRG1 in infarction region and
regenerate cardiomyocytes (Figure 8).
Discussion
In this study, we demonstrated that introducing ERBB4 into
MSCs not only ameliorated MSC survival potential, but
also stimulated cardiomyocyte regeneration. Most impor-
tantly, for the first time, we identified a positive-feedback
autocrine loop in the NRG1-ERBB4 signaling pathway.
ERBB4 overexpression potentiated MSC survival in the
infarcted heart, and enhanced NRG1 generation to restore
the declining NRG1 in the infarcted region and stimulate
cardiomyocyte division.
Current evidence supports the essential roles of NRG1 and
ERBB family in myocardial physiology. In mice that lacked
functional NRG1, ERBB2 or ERBB4 signaling, the primitive
ventricles failed to undergo expansion and trabeculation,
leading to abnormally thin myocardium and enlarged ven-
tricles that cause embryonic lethality at E10.5.31,32 In adult
hearts, NRG1-ERBB4 signaling modulates cell growth,
survival, sarcomere structure and the re-entry of cardiomyo-
cytes into the cell cycle.11 These data collectively suggest that
the NRG1-ERBB pathway has a vital role in the heart under
adverse physiological and pathological circumstances.
Increasing the activity of the NRG1-ERBB signaling complex
might provide a viable strategy for treating heart failure.
By transplanting MSC-ERBB4 into the infarcted myocardium,
we established an intersection that benefits both MSCs and host
myocytes and built a reciprocal relationship between the cells,
either endogenous or exogenous, and the surrounding milieu
(Figure 8): shows cells in the damaged region release cytokines
that attract the infused MSC-ERBB4,33,34 and NRG1 may be
involved in the chemotaxis process; the presence of NRG1 in the
e
Figure 6 (Continued)
Figure 7 Transplantation of MSC-ERBB4 restores reduced NRG1 in MI region.
The model of MI was achieved by LAD ligation, resulting in decreasing NRG1 in the
infarct region. Neither MSCe nor NRG1 injection improved the situation, but MSC-
ERBB4 transplantation restored NRG1 to a level comparable with that of the normal
myocardium
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infarcted region improved MSC-ERBB4 cell survival by attenuat-
ingapoptosis viaPI3K/Akt pathway;MSC-ERBB4upregulates the
synthesis and secretion of its ligand NRG1, the latter of which
stimulates cardiomyocyte cell cycle re-entry and a rebound in
NRG1 level in the infarctedmyocardium.MSC-ERBB4mayact as
amoving ‘NRG1 factory’ in an autocrine and paracrine manner to
activate survival signaling in MSCs and the host cardimyocytes. It
should be noted that although ERBB4 overexpression leads to
NRG1 secretion, the self-activated NRG1 is not sufficient to alter
the cell behavior. Cell mobility and anti-apoptosis of MSC-ERBB4
differed little to that ofMSCeunlessadditionalNRG1wasprovided
(Figure 3bii and 3c), suggesting that this autocrine loop is likely
autonomic, and thus reduces the risk of malignancy (Figure 1d).
In summary, ERBB4 overexpression potentiates MSC survival
in the infarcted heart, enhances NRG1 generation to restore the
declining NRG1 in the infarcted region and stimulates cardiomyo-
cyte division. ERBB4 overexpression in MSCs may provide a
novel molecular strategy for myocardial repair and regeneration.
Materials and Methods
An expanded Materials and Methods section is included in the Supplementary Materials.
MSCswere isolated and cultured as previously described.35 Characterized MSC at
passage 4–8 were used in the study. Expression profile of NRG1-ERBB signaling was
examined by RT-PCR. MSC were infected with lentivirus containing ERBB4-GFP
(pER4-GFP) or GFP (pGFP) and stably transduced. The efficiency of gene delivery
was confirmed by RT-PCR, western blotting (ERBB4 (Abcam, Cambridge, UK;
ab19391); p-ERBB4 (Abcam, ab109273); β-actin (Santa Cruz, Dallas, TX, USA;
SC-47778)) and cell fluorescence before further transplantation into the infarcted
hearts or in vitro experiments. Tri-lineage differentiation capability was examined after
genetic modification. Tumor formation was examined by subcutaneously transplant-
ing 1 × 106 MSCe or MSC-ERBB4 into NOD-SCID mice, with mESCs inoculated to
the other side of the animal as controls (n= 4). Tumorigenesis in mice was kept under
observation for 8 weeks. A MI model was constructed by permanent ligation of the
LAD in female C57/B6 mice (6–8 weeks) as described previously.36,37 Immediately
following LAD ligation, NRG1 (Abm, Richmond, BC, Canada; RP155006, 100 μg/kg),
or 3 × 105 transduced MSCs suspended in 30 μL PBS were injected at 5 sites in the
anterior and posterior infarct border zones of the ischemic myocardium. Animal care
and all experimental procedures adhered to the Guidelines for the Care and Use of
Laboratory Animals prepared by the National Academy of Sciences and published by
the National Institutes of Health, and were approved by the Committee on the Use of
Live Animals in Teaching and Research at the University of Hong Kong. Invasive
cardiac hemodynamic assessment was performed 4 weeks after MI to measure the
cardiac function. Masson trichrome staining (KeyGEN, Nanjing, China; KGMST-8003)
was used to determine cardiac remodeling. Immunofluorescence staining using anti-
GFP antibody (Santa Cruz, SC-8334) was performed to determine cell survival
in vivo. Double staining using Ki67 (Abcam, ab15580), a cell proliferation marker, and
α-actinin (Sigma, St. Louis, MO, USA; A7811), a mature cardiomyocyte marker, was
performed to determine cardiomyocytes in the active cell cycle phase. TUNEL
(Keygen, KGA7062) and α-actinin double staining was performed to quantify
apoptotic cardiomyocytes at 48 h post-MI in vivo. Cultured MSCs, with or without
ERBB4 expression, were challenged with hypoxia (1% O2, 4% CO2). Cell mobility and
anti-apoptosis were analyzed using transwell assay and Annexin V/PI staining
(eBioscience, San Diego, CA, USA; 88-8007-74), respectively. Western blotting
against p-Akt (Cell-Signaling, Boston, MA, USA; 9611) Bcl-2 (Cell-Signaling, 2870)
were used to determine the mechanism involved in anti-apoptotic effects. To test the
protective effect of paracrine factors secreted by MSCs against hypoxia-induced cell
death, conditioned medium fromMSC hypoxic cultures was added to cardiomyocytes.
MTT, Ki67 staining, cell senescence-associated β-galactosidase staining (Millipore,
Boston, MA, USA; KAA002) and western blotting against p-Akt was conducted, to
evaluate cell growth, proliferation, anti-aging and anti-apoptosis effects, respectively.
Figure 8 Schematic diagram of the NRG1-ERBB4-NRG1 autocrine pathway. Genetic manipulation of ERBB4 into MSC provides irreplaceable partner to ERBB2, the latter of
which forms an ERBB2/ERBB4 heterodimer that binds to its ligand NRG1. ERBB4 can bind to NRG1 by forming a homodimer. Activation of the NRG1-ERBB pathway in MSC-
ERBB4 enhances cell mobility and anti-apoptosis through the phosphorylation of Akt. Overexpressing ERBB4 in turn regulates the synthesis and secretion of NRG1.
The released NRG1 contributes to restore the declined NRG1 level in the infarcted region and support cell growth, dividing and anti-apoptosis of cardiomyocytes. By ERBB4
overexpression in MSCs, we figured out a novel approach that benefits both MSCs and cardiomyocytes, and enable an effective myocardial repair after ischemia
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ELISA (USCN, Houston, TX, USA; E91866Mu) and western blotting against NRG1
(Santa Cruz, SC-348) were used to assess the expression after ERBB4
overexpression in MSCs. RT-PCR was performed to measure the changes of
NRG1-ERBB signaling after ERBB4 overexpression in MSCs. To verify an autocrine
loop in the NRG1-ERBB4-NRG1 pathway, a multiple transient transfection using
pER4-GFP was performed, in which transfection efficiency was detected by GFP
fluorescence and NRG1 expression was detected by western blotting. To validate the
role of self-activated NRG1 on cardiomyocytes, anti-NRG1 antibody (Santa Cruz,
SC-348, 10 μg/mL) was applied to the conditioned medium of MSC-ERBB4, and cell
growth, proliferation and senescence were evaluated. western Blotting was performed to
assess NRG1 level in the infarcted myocardium and remote region after NRG1 and stem
cell injection. Student's t-test or one or two-way ANOVA with the Bonferroni post hoc test
were applied to determine the statistical significance (Po0.05).
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